Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295550 | 0.88 | KMT2A (0.60) | KMT2ATSHRHTTLMNAALDH1A1 | |
| SCHEMBL1230603 | 0.87 | KMT2A (0.56) | KMT2ATSHRHTTLMNAALDH1A1 | |
| Hydrochloric Acid SCHEMBL2290641 | 0.86 | KMT2A (0.56) | KMT2ATSHRHTTLMNAALDH1A1 | |
| SCHEMBL6646760 | 0.84 | KMT2A (0.67) | KMT2ATSHRHTTLMNAALDH1A1 | |
| Acetic Acid SCHEMBL1232023 | 0.83 | KMT2A (0.55) | KMT2ATSHRHTTLMNAALDH1A1 | |
| SCHEMBL18890998 | 0.83 | PDE5A (0.50) | KMT2ATSHRHTTLMNAALDH1A1 | |
| SCHEMBL18891204 | 0.82 | TSHR (0.56) | KMT2ATSHRHTTLMNAALDH1A1 | |
| SCHEMBL1668350 | 0.82 | KMT2A (0.56) | KMT2ATSHRHTTLMNAALDH1A1 | |
| SCHEMBL18430905 | 0.81 | TSHR (0.55) | KMT2ATSHRHTTLMNAALDH1A1 | |
| SCHEMBL21755554 | 0.78 | PDE5A (0.52) | KMT2ATSHRHTTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190849-A1 | PROCESSES FOR THE PREPARATION OF VARDENAFIL | RANBAXY LABORATORIES LIMITED (IN) | 2012-07-26 | — | — | US | disclosed |
| US-20120190849-A1 | PROCESSES FOR THE PREPARATION OF VARDENAFIL | RANBAXY LABORATORIES LIMITED (IN) | 2012-07-26 | — | — | US | disclosed |
| WO-2011016016-A1 | PROCESSES FOR THE PREPARATION OF VARDENAFIL | RANBAXY LABORATORIES LIMITED (IN) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190849-A1 | PROCESSES FOR THE PREPARATION OF VARDENAFIL | PDE5A, PDE3A, PDE3B | KMT2A 1594/4885TSHR 4781/4885HTT 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.